Lyell Immunopharma filings document the regulatory record of a Nasdaq-listed clinical biotechnology company developing next-generation CAR T-cell therapies. Its 8-K reports furnish operating results and business updates for ronde-cel in large B-cell lymphoma and LYL273 in metastatic colorectal cancer and other GCC-expressing cancers, along with cash, financing and clinical-program disclosures.
The company’s filings also cover material agreements, including licensing rights for LYL273, and governance matters such as annual-meeting proposals, director elections, auditor ratification, executive compensation votes, officer appointments and compensatory arrangements. Securities disclosures identify Lyell’s common stock listed on the Nasdaq Global Select Market.
Lyell Immunopharma announced that it issued a press release reporting its financial results for the quarter ended June 30, 2025, and attached that release as Exhibit 99.1 to this Form 8-K. The filing states the information is being furnished and shall not be deemed filed for purposes of Section 18 of the Exchange Act, meaning it is not subject to the liabilities of that section and is not incorporated by reference into other filings unless expressly referenced. The document also lists the company’s common stock as LYEL on the NASDAQ Global Select Market and is signed on behalf of the company by Mark Meltz, General Counsel and Corporate Secretary.
ARCH Venture Fund XIII, L.P. and affiliated entities have filed a Form 3 disclosing their initial beneficial ownership in Lyell Immunopharma (LYEL).
- Shares acquired: 938,438 common shares
- Purchase date / price: 25-Jul-2025 at $13.32 per share (per securities-purchase agreement dated 24-Jul-2025)
- Ownership status: Indirectly held through ARCH Venture Fund XIII, L.P.; the group is now classified as a 10 %+ owner under Section 16(a)
- Control structure: ARCH Venture Partners XIII, L.P. is the GP of the fund, managed by ARCH Venture Partners XIII, LLC whose investment committee members—Keith Crandell, Robert Nelsen, Kristina Burow, Paul Berns and Steven Gillis—share voting/dispositive power but disclaim beneficial ownership beyond pecuniary interest
The filing signals a sizeable insider position (≈ $12.5 million) and provides investors with updated information on Lyell’s ownership structure.
Lyell Immunopharma (Nasdaq:LYEL) filed an 8-K (Item 3.02) disclosing that the clinical milestone embedded in its October 2024 ImmPACT Bio merger has been met. The achievement obligates Lyell to issue 625,000 unregistered common shares (post 1-for-20 reverse split) to former ImmPACT securityholders in a private placement relying on the Section 4(a)(2) exemption.
The shares represent additional equity consideration; no cash will be paid. While the filing does not quantify the percentage of outstanding stock, the issuance will incrementally dilute current holders. The milestone confirms progress for ImmPACT’s next-generation CAR T-cell candidate, potentially accelerating Lyell’s cell-therapy pipeline.
- Shares are restricted and cannot be publicly resold without registration or another exemption.
- No other material items were reported.